Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases.
Brain metastases
Follow-up
MRI
Magnetic resonance imaging
Monitoring
Radiosurgery
Stereotactic radiotherapy
Surgical cavity
Surveillance
Tumor bed
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
14 Mar 2019
14 Mar 2019
Historique:
received:
21
11
2018
accepted:
05
03
2019
entrez:
16
3
2019
pubmed:
16
3
2019
medline:
29
5
2019
Statut:
epublish
Résumé
Administering stereotactic radiotherapy to the surgical cavity and thus omitting postoperative whole brain radiotherapy (WBRT) is a favored strategy in limited metastatic brain disease. Little is known about the impact of regular magnetic resonance imaging follow-up (MRI FU) in such patient cohorts. The aim of this study is to examine the impact of regular MRI FU and to report the oncological outcomes of patients with one to three brain metastases (BMs) treated with stereotactic radiosurgery (SRS) or hypo-fractionated stereotactic radiotherapy (HFSRT) to the surgical cavity. We retrospectively analyzed patients who received SRS or HFSRT to the surgical cavity after resection of one to two BMs. Additional, non-resected BMs were managed with SRS alone. Survival was estimated by the Kaplan-Meier method. Prognostic factors were examined with the log-rank test and Cox proportional hazards model. Regular MRI FU was defined as performing a brain MRI 3 months after radiotherapy (RT) and/or performing ≥1 brain MRI per 180 days. Primary endpoint was local control (LC). Secondary endpoints were distant brain control (DBC), overall survival (OS) and the correlation between regular MRI FU and overall survival (OS), symptom-free survival (SFS), deferment of WBRT and WBRT-free survival (WFS). Overall, 75 patients were enrolled. One, 2 and 3 BMs were seen in 63 (84%), 11 (15%) and 1 (1%) patients, respectively. Forty (53%) patients underwent MRI FU 3 months after RT and 38 (51%) patients received ≥1 brain MRI per 180 days. Median OS was 19.4 months (95% CI: 13.2-25.6 months). Actuarial LC, DBC and OS at 1 year were 72% (95% CI: 60-83%), 60% (95% CI: 48-72%) and 66% (95% CI: 53-76%), respectively. A planning target volume > 15 cm Our results regarding oncological outcomes consist with the current data from the literature. Surprisingly, regular MRI FU did not result in increased OS, SFS, WFS or deferment of WBRT in our cohort consisting mainly of patients with a single and resected BM. Therefore, the impact of regular MRI FU needs prospective evaluation. Project ID: 2017-00033, retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Administering stereotactic radiotherapy to the surgical cavity and thus omitting postoperative whole brain radiotherapy (WBRT) is a favored strategy in limited metastatic brain disease. Little is known about the impact of regular magnetic resonance imaging follow-up (MRI FU) in such patient cohorts. The aim of this study is to examine the impact of regular MRI FU and to report the oncological outcomes of patients with one to three brain metastases (BMs) treated with stereotactic radiosurgery (SRS) or hypo-fractionated stereotactic radiotherapy (HFSRT) to the surgical cavity.
METHODS
METHODS
We retrospectively analyzed patients who received SRS or HFSRT to the surgical cavity after resection of one to two BMs. Additional, non-resected BMs were managed with SRS alone. Survival was estimated by the Kaplan-Meier method. Prognostic factors were examined with the log-rank test and Cox proportional hazards model. Regular MRI FU was defined as performing a brain MRI 3 months after radiotherapy (RT) and/or performing ≥1 brain MRI per 180 days. Primary endpoint was local control (LC). Secondary endpoints were distant brain control (DBC), overall survival (OS) and the correlation between regular MRI FU and overall survival (OS), symptom-free survival (SFS), deferment of WBRT and WBRT-free survival (WFS).
RESULTS
RESULTS
Overall, 75 patients were enrolled. One, 2 and 3 BMs were seen in 63 (84%), 11 (15%) and 1 (1%) patients, respectively. Forty (53%) patients underwent MRI FU 3 months after RT and 38 (51%) patients received ≥1 brain MRI per 180 days. Median OS was 19.4 months (95% CI: 13.2-25.6 months). Actuarial LC, DBC and OS at 1 year were 72% (95% CI: 60-83%), 60% (95% CI: 48-72%) and 66% (95% CI: 53-76%), respectively. A planning target volume > 15 cm
CONCLUSION
CONCLUSIONS
Our results regarding oncological outcomes consist with the current data from the literature. Surprisingly, regular MRI FU did not result in increased OS, SFS, WFS or deferment of WBRT in our cohort consisting mainly of patients with a single and resected BM. Therefore, the impact of regular MRI FU needs prospective evaluation.
TRIAL REGISTRATION
BACKGROUND
Project ID: 2017-00033, retrospectively registered.
Identifiants
pubmed: 30871597
doi: 10.1186/s13014-019-1252-x
pii: 10.1186/s13014-019-1252-x
pmc: PMC6417038
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45Références
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8
pubmed: 10802351
Cancer Treat Rev. 2003 Dec;29(6):533-40
pubmed: 14585263
J Neurooncol. 2005 Oct;75(1):5-14
pubmed: 16215811
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):187-93
pubmed: 17881139
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1134-9
pubmed: 19932944
J Neurosurg. 2011 Mar;114(3):763-8
pubmed: 20225924
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
J Neurosurg. 2011 Jun;114(6):1585-91
pubmed: 21166567
J Exp Clin Cancer Res. 2011 Jan 18;30:10
pubmed: 21244695
J Neurosurg. 2011 Sep;115(3):499-504
pubmed: 21639696
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
J Clin Oncol. 2012 Feb 1;30(4):419-25
pubmed: 22203767
J Cancer Res Clin Oncol. 2012 Sep;138(9):1523-9
pubmed: 22526164
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):336-42
pubmed: 22652105
Neurosurgery. 2013 Mar;72(3):317-25; discussion 325-6
pubmed: 23208065
Cancer Treat Rev. 2014 Feb;40(1):48-59
pubmed: 23810288
Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):130-6
pubmed: 24331659
Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):137-42
pubmed: 24331660
Cancer. 2014 Feb 1;120(3):433-41
pubmed: 24452675
Lancet Oncol. 2014 Apr;15(4):387-95
pubmed: 24621620
Neurosurgery. 2015 Feb;76(2):150-6; discussion 156-7; quiz 157
pubmed: 25549189
Cancer Imaging. 2014 Apr 22;14:8
pubmed: 25608557
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
Curr Oncol. 2016 Oct;23(5):356-360
pubmed: 27803601
Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):131-141
pubmed: 28586952
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
J Neurooncol. 2018 Sep;139(2):461-467
pubmed: 29740743
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
JAMA. 1998 Nov 4;280(17):1485-9
pubmed: 9809728